Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Communications"
DOI: 10.1002/cac2.12524
Abstract: The initial phase II stuty (NCT03215693) demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib‐refractory, anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Herein, we reported the updated data on overall… read more here.
Keywords: phase study; alk positive; crizotinib refractory; overall survival ... See more keywords